Suppr超能文献

利尿剂、钙拮抗剂和α受体阻滞剂对高血压患者胰岛素敏感性和糖耐量的影响。

Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients.

作者信息

Ramsay L E, Yeo W W, Jackson P R

机构信息

Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, England.

出版信息

J Cardiovasc Pharmacol. 1992;20 Suppl 11:S49-53; discussion S53-4.

PMID:1284144
Abstract

Treatment with thiazide diuretics causes impaired glucose tolerance, biochemical diabetes, and insulin resistance. The effect of diuretics on glucose tolerance is clearly dose-related. Spironolactone does not impair glucose tolerance, even at high dosage, but differences among other diuretics could be due to comparisons at doses that are not equal. Diuretic-induced changes in glucose metabolism are not conclusively related to altered potassium homeostasis, and impaired glucose tolerance occurs even when relatively low doses of thiazide are combined with potassium-sparing agents. The effects of diuretics on glucose homeostasis are in large part and probably entirely reversible. These disturbances of glucose metabolism have been detected only by detailed biochemical testing, and their clinical relevance is uncertain. In established diabetes, diuretics have a rapid and substantial adverse effect on metabolic control. In nondiabetic subjects, diuretics rarely cause or trigger a serious hyperosmolar nonketotic diabetic syndrome. Otherwise, it is not known whether the metabolic changes cause clinical diabetes or lead to microvascular complications in the long term. Evidence from large outcome trials suggests that biochemical diabetes, glucose intolerance, and insulin resistance do not increase the risk of coronary heart disease in treated hypertensive patients. Diuretics should be avoided in patients with diabetes unless their use is essential. Otherwise, a low dose of thiazide remains as excellent choice for first-line antihypertensive therapy. Dihydropyridine calcium antagonists, diltiazem, and verapamil appear to have no important effects on glucose homeostasis. There is very limited evidence that selective alpha-antagonists increase insulin sensitivity. The importance of metabolic differences between drug classes will be established only by comparative outcome trials with coronary events as the end point.

摘要

噻嗪类利尿剂治疗可导致糖耐量受损、生化性糖尿病和胰岛素抵抗。利尿剂对糖耐量的影响与剂量明显相关。螺内酯即使大剂量使用也不会损害糖耐量,但其他利尿剂之间的差异可能是由于所比较的剂量不相等所致。利尿剂引起的糖代谢变化与钾稳态改变并无确凿关联,即使将相对低剂量的噻嗪类药物与保钾药物合用,仍会出现糖耐量受损。利尿剂对葡萄糖稳态的影响在很大程度上且可能完全是可逆的。这些糖代谢紊乱仅通过详细的生化检测才能发现,其临床相关性尚不确定。在已确诊的糖尿病患者中,利尿剂对代谢控制有迅速且显著的不良影响。在非糖尿病患者中,利尿剂很少引发严重的高渗性非酮症糖尿病综合征。除此之外,尚不清楚这些代谢变化是否会导致临床糖尿病或长期引发微血管并发症。大型结局试验的证据表明,生化性糖尿病、糖耐量异常和胰岛素抵抗并不会增加接受治疗的高血压患者患冠心病的风险。糖尿病患者应避免使用利尿剂,除非其使用必不可少。否则,低剂量噻嗪类药物仍是一线抗高血压治疗的理想选择。二氢吡啶类钙拮抗剂、地尔硫䓬和维拉帕米似乎对葡萄糖稳态没有重要影响。仅有非常有限的证据表明选择性α受体拮抗剂可提高胰岛素敏感性。只有通过以冠心病事件为终点的比较性结局试验,才能确定不同药物类别之间代谢差异的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验